UNSPSC 51294206: Paraxazone

This classification denotes an anxiolytic with the molecular formula C10H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H6ON8WA7L, chemically known as 2,3-dihydro-3-oxo-4h-1,4-benzoxazine-4-acetamide. but generally known as paraxazone, which bears US NIH Compound Identifier 3047812. European Medicines Agency schedules Paraxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09619MIG.

UNSPSC 51294206 Paraxazone is a Commodity code that captures pharmaceutical products and related health-delivery systems procured by state and local health authorities, though recent solicitations under this code show activity spanning naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution rather than paraxazone specifically. State and local governments buy opioid-reversal medications, drug deactivation systems, and generic pharmaceuticals through this code to support public health initiatives, community health programs, and state employee health benefit administration. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP).

Recent activity spans Florida, Texas, and Minnesota, with the most visible solicitations including Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with quarterly deliveries to the Seminole County Community Health Building; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) requesting vendor capabilities for a direct-to-manufacturer prescription program to support therapeutic pharmacy initiatives outside traditional pharmacy benefit manager arrangements; and MMCAP's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson to participating state and local government facilities across multiple states including Oregon. The MMCAP procurement emphasizes price competitiveness (75 percent of evaluation weight), cGMP and Drug Supply Chain Security Act compliance, and maintenance of relationships with authorized wholesalers; Seminole County's naloxone procurement requires electronic bidding through the county e-Procurement Portal with fixed pricing and includes a three-month probationary termination clause.